Seasoned financial executive with a strong track record in the EMEA region. As Group CFO at TWITI Investments, a leading BioTech and MedTech investment fund, he oversees financial operations and strategic planning. With extensive experience in diverse industries and a deep understanding of global financial regulations, Mencel drives business growth and maximizes shareholder value. His career spans leadership roles at Raisead, Cottonex Group, PWB Awbud, Grass Cavagna Group, and EGIS Pharmaceuticals. Holding an FCMA, CGMA, he is a strategic financial leader with a proven ability to deliver results.

Distinguished Polish oncologist and academic. With a PhD in medical sciences, he holds a professorship at the Institute of Health Sciences, University of Natural Sciences and Humanities in Siedlce. His academic journey includes doctoral studies completed in 2008, followed by habilitation in 2014. Prior to his current position, Dr. Bodnar contributed his expertise to institutions such as the Military Medical Institute in Warsaw, the University of Warmia and Mazury in Olsztyn, and the Warmia and Mazury Oncology Center. Since 2021, he has been leading the Siedlce Oncology Center. Dr. Bodnar is a prolific researcher with over 200 scientific publications to his name, focusing primarily on oncology.

Dr. Marszałek obtained her PhD in Biophysics from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. She has several years of experience in drug development in both academia and biotech industry. She is an author of several scientific papers, honored with two international scholarships and several national, and international awards. At Cellis, she oversees biochemical research team and co-builds new strategies for protein-drug design, development, and manufacturing.

Dr. Gabrusiewicz spent over six years at MD Anderson Cancer Center at Brain Tumor Center (Houston, USA) exploring glioblastoma microenvironment and elucidating the mechanisms of tumor-mediated immune suppression. He has many years of experience in cell therapy development for solid tumors (CAR-T, TCR-T, gamma/delta-T and CAR-monocytes/macrophages). Previously he worked at Kiromic Biopharma Inc., Ziopharm Oncology Inc. (currently Alaunos Therapeutics), Carisma Therapeutics Inc. and Bellicum Pharmaceuticals Inc. (USA).

Dr. Taciak obtained his PhD from Warsaw University of Life Sciences in 2019. He was a primary recipient of a grant from the National Science Centre to study an impact of macrophages on Wnt signaling pathway in cancer cells. During his PhD program he spent several months at Bilkent University, Turkey and in the laboratory of prof. Jeffrey Pollard at the University of Edinburgh, UK. Currently, he leads a team of young scientists at R&D site testing killing abilities of MDC in variety of cancer types.

Experienced Swiss lawyer and mediator with a deep understanding of Swiss law and business environment. With a law degree and certifications in trust and estate practice (TEP) and arbitration (ACIArb Mediation), she provides comprehensive legal advice and dispute resolution services to SMEs. As the founder of CMK Services, she has built a reputation for delivering tailored solutions in six languages: English, German, French, Russian, Polish, and Italian.

Group Leader in the Department of Biochemical Sciences at Sapienza University of Rome. During his scientific career he worked at the following scientific centers: Université de Luminy II Marseille (FR), Albert Einstein College of Medicine (USA), National Research Council CNR (IT). He is a co-founder of number of companies, majority of them have been sold or acquired. Currently, he serves as a consultant for a number of biotech companies.

Dr. Simpson has 15 years of experience in biologics development and commercialization with Cobra Biologics, Eden Biodesign and Actavis, and supported IP Group to develop Glythera’s business strategy and fundraising activities. Currently he is a CEO at Iksuda Therapeutics and non-executive Director at Leaf Expression Systems.

Dr. Weiss has many years of clinical and scientific experience in brain tumors. Currently, he is Senior Physician and Researcher at University Hospital of Zurich (Switzerland). He works at Neuroscience Center Zurich in a team of Prof. Michael Weller where Cellis runs glioblastoma project.

With over 25 years of experience in the pharmaceutical industry, Dr. Brown brings a wealth of knowledge in both small molecule and biological drug discovery. His career spans senior leadership roles at companies such as British Biotech, OSI Pharmaceuticals, Piramed Pharma, Cancer Research Technology, and CellCentric. Dr. Brown has a proven track record in managing strategic partnerships, leading oncology programs from inception to clinical trials, and driving innovation in the field. He holds a PhD from the University of Oxford and an MBA from Oxford Brookes University.

Distinguished hematologist and transfusion medicine specialist. With a career spanning decades, she has made significant contributions to the field. As former head of the Hematology Clinic at the Institute of Hematology and Transfusion Medicine in Warsaw and subsequent leader of the Transfusion Medicine Department, she has held pivotal roles in Polish healthcare. Professor Łętowska’s expertise is reflected in her extensive research, with over 150 publications on hematology, transfusion medicine, hemostasis, and porphyria. Her leadership in the field is evident through her role as a former national consultant and chairwoman of the Transfusion Medicine Section of the Polish Society of Hematologists and Transfusion Medicine.

Veterinary pathologist affiliated with the Institute of Veterinary Pathology at the Freie Universität Berlin. He holds a Diplomate status with the American College of Veterinary Pathologists (ACVP) and is a specialized veterinarian in pathology. With expertise in histology, histopathology, immunohistochemistry, cancer diagnostics, and veterinary diagnostics for both small animals and clinical settings, Prof. Klopfleisch has made significant contributions to the field. He has authored 450 publications, and his work has been cited nearly 8,000 times, reflecting his impact and recognition in veterinary science and pathology.